

Ref: FOI/GS/ID 9593

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

09 December 2024

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Lung cancer.

You asked: All questions are shown as received by the Trust.

Question One: How many early-stage (non-metastatic or Stages 2-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- a. *Atezolizumab (Tecentriq)*
- b. *Durvalumab (Imfinzi)*
- c. *Nivolumab (Opdivo)*
- d. *Pembrolizumab (Keytruda)*
- e. *Chemotherapy*
- f. *Radiotherapy*
- g. *Chemotherapy AND Radiotherapy*

Question Two: How many patients has your Trust treated in total in the past 3 months for

- a. *Stage 2 Non Small Cell Lung Cancer*
- b. *Stage 3 Non Small Cell Lung Cancer*

Question Three: How many patients who received Pembrolizumab for Non Small Cell Lung Cancer (NSCLC) (any stage) in the last 3 months, received: Pembrolizumab Monotherapy

- a. *Treatment every 3 weeks (200mg, Q3W)*
 - b. *Treatment every 6 weeks (400mg, Q6W)*
- Pembrolizumab in combination with chemotherapy*

- a. *Treatment every 3 weeks (200mg, Q3W)*
- b. *Treatment every 6 weeks (400mg, Q6W)*

Trust response:

1.
 - a. 4

- b. 3
- c. 1
- d. 17
- e. 34
- f. 30
- g. 10

2.

- a. 20
- b. 51

3.

Pembrolizumab Monotherapy

- a. 4
- b. 10

Pembrolizumab in combination with chemotherapy

- a. 15
- b. 1